Reading the tape
NASDAQ: VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
Market Cap
$94.65M
52w High
$65.80
52w Low
$2.62
P/E
-0.20
Volume
1.07M
Outstanding Shares
6.85M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -5.09%FCF (TTM): -43.81%
What changed
The stock fell 5.09% over the last year. Free cash flow declined 43.81% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.
CEOJean-Paul Kress
SectorHealthcare
IndustryBiotechnology
Employees159
IPO dateFeb 5, 2021
Valuation
Forward P/E—
EV/EBITDA0.72
Enterprise value-$264.36M
Stock splits
Sep 19, 2025↓ Reverse
Every 20 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE423.57%▲450.21%vs FY2024
Analyst consensus
RatingBuy
Target price$38.50▲178.78%
10
Buy
3
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 13, 2026
Q2 FY26 · EPS est -$0.75 · Revenue est —
View